Osteopore Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Osteopore hat ein Gesamteigenkapital von A$432.6K und eine Gesamtverschuldung von A$1.1M, was einen Verschuldungsgrad von 246% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen A$3.3M bzw. A$2.9M.

Wichtige Informationen

59.8%

Verhältnis von Schulden zu Eigenkapital

AU$1.08m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	AU$2.28m
Eigenkapital	AU$1.80m
Gesamtverbindlichkeiten	AU$2.74m
Gesamtvermögen	AU$4.55m

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: OSXDie kurzfristigen Aktiva des Unternehmens (A$3.7M) übersteigen seine kurzfristigen Passiva (A$2.7M).

Langfristige Verbindlichkeiten: OSXDie kurzfristigen Vermögenswerte des Unternehmens (A$3.7M) übersteigen seine langfristigen Verbindlichkeiten (A$5.6K).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: OSX über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: OSXDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 29.1% auf 59.8% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: OSX hat auf der Grundlage seines derzeitigen freier Cashflows weniger als ein Jahr Liquiditätsspielraum.

Vorhersage Cash Runway: OSX hat weniger als ein Jahr Liquiditätsreserven, wenn der freie Cashflow weiterhin mit den historischen Raten von 16.4% pro Jahr abnimmt

Osteopore Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Recent updates

Osteopore Limited Appoints Yujing Lim as Executive Director

New major risk - Financial position

New major risk - Shareholder dilution

Less than half of directors are independent

Osteopore Limited, Annual General Meeting, May 30, 2024

Less than half of directors are independent

Osteopore Limited has filed a Follow-on Equity Offering in the amount of AUD 2.99532 million.

Full year 2023 earnings released: AU$0.031 loss per share (vs AU$0.51 loss in FY 2022)

Osteopore Limited announced that it expects to receive SGD 1 million in funding

Osteopore Limited announced that it expects to receive SGD 1 million in funding

Less than half of directors are independent

Less than half of directors are independent

Osteopore Limited Announces Resignation of Deborah Ho as Joint Company Secretary

First half 2023 earnings released: AU$0.019 loss per share (vs AU$0.017 loss in 1H 2022)

Full year 2022 earnings released: AU$0.034 loss per share (vs AU$0.031 loss in FY 2021)

Osteopore Limited Enters Orthopaedic Market in Great Britain

Osteopore Limited Announces Appointment of Kellie Davis as Joint Company Secretary, Effective 26 January 2023

Less than half of directors are independent

Osteopore Limited (ASX:OSX) agreed to acquire Businesses Of Lomic Korea, 3D Aesthetic Solutions, 3D Healthcare Solutions And 3D Aesthetic Medical Lim Jae Hoon from Lim Jae Hoon for AUD2.05 million.

Less than half of directors are independent

Less than half of directors are independent

First half 2022 earnings released: AU$0.017 loss per share (vs AU$0.012 loss in 1H 2021)

Insider recently bought AU$1.9m worth of stock

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Osteopore Limited Announces Appointment of Dr. Lim Jing as Chief Operating Officer

Osteopore Limited, Annual General Meeting, May 31, 2022

Less than half of directors are independent

Osteopore Limited Announces Resignation of Vlado Bosanac as Non-Executive Director

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Less than half of directors are independent

Non Executive Chairman Brett Sandercock has left the company

Full year 2020 earnings released: AU$0.018 loss per share (vs AU$0.083 loss in FY 2019)

Full year 2020 earnings released: AU$0.018 loss per share (vs AU$0.083 loss in FY 2019)

Osteopore Limited Announces A Cooperation Agreement with Terumo Blood and Cell Technologies

Osteopore International Collaborates with Maastricht University Medical Centre to Develop Implant Solution That Prevents Leg Amputations

Osteopore Limited Signs Distribution Agreement with MTG Medizintechnik Göhl

Osteopore Limited Announce the Appointment of Carl Runde as Chief Financial Officer

First half earnings released

Osteopore Limited has completed a Follow-on Equity Offering in the amount of AUD 8.5 million.

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen